Top Page
Anebulo Pharmaceuticals
(OTC:ANEB)
Anebulo Pharmaceuticals (ANEB) vs. SPDR S&P 500 ETF (SPY)
Anebulo Pharmaceuticals Business Overview & Revenue Model
Anebulo Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.32M | -8.10M | -7.79M | -11.73M | -6.83M | -30.24M |
| Net Income | -7.98M | -8.48M | -8.20M | -11.73M | -6.83M | -30.25M |
Balance Sheet | ||||||
| Total Assets | 9.42M | 12.15M | 4.07M | 11.67M | 15.58M | 21.65M |
| Cash, Cash Equivalents and Short-Term Investments | 9.04M | 11.63M | 3.09M | 11.25M | 14.55M | 19.99M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.49M | 487.69K | 260.58K | 1.07M | 512.53K | 241.63K |
| Stockholders Equity | 7.94M | 11.66M | 3.81M | 10.60M | 15.07M | 21.41M |
Cash Flow | ||||||
| Free Cash Flow | -5.84M | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M |
| Operating Cash Flow | -5.84M | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -116.66K | 14.88M | -62.35K | 6.38M | 0.00 | 21.83M |
Anebulo Pharmaceuticals Technical Analysis
Anebulo Pharmaceuticals Risk Analysis
Anebulo Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $281.15M | -2.38 | -30.93% | ― | ― | 69.30% | |
56 Neutral | $754.60M | -1.92 | -45.01% | ― | ― | -7.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $218.57M | -0.39 | ― | ― | -63.96% | -28.50% | |
45 Neutral | $24.97M | -0.37 | ― | ― | -33.00% | 54.91% | |
43 Neutral | $71.55M | -11.85 | 1.94% | ― | ― | ― | |
40 Underperform | $26.95M | -5.19 | -74.58% | ― | ― | 23.10% |
Anebulo Pharmaceuticals Corporate Events
On February 5, 2026, Anebulo Pharmaceuticals’ board approved the voluntary delisting of the company’s common stock from the Nasdaq Capital Market and the subsequent deregistration of its shares with the U.S. Securities and Exchange Commission, a move publicly announced in a press release dated February 6, 2026. While the company remains in compliance with Nasdaq listing standards, the board concluded that the costs and administrative burdens of being a publicly listed, SEC-reporting company outweigh the benefits, especially as it focuses resources on advancing its lead selonabant program. The delisting is expected to become effective on February 27, 2026, after the planned filing of Form 25, with a Form 15 to be filed around the same date to terminate SEC registration and suspend periodic reporting obligations, after which trading in Anebulo’s shares would be limited to private transactions and potentially over-the-counter markets, altering liquidity and transparency for existing shareholders.
The most recent analyst rating on (ANEB) stock is a Sell with a $0.91 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.
On January 29, 2026, Anebulo Pharmaceuticals reported the final results of its voluntary self-tender offer, which expired on January 26, 2026, to repurchase up to 300,000 shares of common stock at $3.50 per share. The offer was heavily oversubscribed, with 4,907,881 shares validly tendered and not withdrawn; Anebulo ultimately bought the full 300,000-share maximum, including 134,306 odd-lot shares accepted in full, at an aggregate cost of about $1.05 million, representing approximately 0.73% of shares outstanding as of January 26, 2026. The shares, other than odd lots, were accepted on a pro rata basis using a final proration factor of 3.47392%, and payment in cash without interest will be made promptly to participating shareholders. Management said the transaction met its goal of offering smaller shareholders a chance to exit at a significant premium to market while modestly shrinking the shareholder base, a move that could streamline the company’s investor roster without materially affecting its capital structure.
The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.
On January 27, 2026, Anebulo Pharmaceuticals reported preliminary results from its voluntary self-tender offer for up to 300,000 shares of its common stock at $3.50 per share in cash, following the offer’s expiration on January 26, 2026. The offer was significantly oversubscribed, with about 4.9 million shares properly tendered, leading the company to expect pro rata acceptance of approximately 300,000 shares—about 0.73% of shares outstanding as of January 26—at an estimated aggregate cost of $1.05 million, excluding fees and expenses. A preliminary proration factor of roughly 3.5% is expected, with “odd lot” tenders to be accepted in full; final share counts and proration will be confirmed after the guaranteed delivery period, and accepted shares will be paid for in cash while unpurchased shares will be returned promptly. The oversubscription suggests robust shareholder interest in the liquidity event and will result in a modest reduction in Anebulo’s share count, with limited but targeted impact on capital allocation and ownership structure.
The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.
On December 22, 2025, Anebulo Pharmaceuticals announced that its board had abandoned a previously proposed large reverse stock split and related special shareholder meeting in favor of launching a voluntary self-tender offer as part of its plan to go private. The company intends to commence a cash tender offer to buy up to 300,000 shares of its common stock at $3.50 per share, for a total of up to $1.05 million, a move aimed at keeping its shareholder count below 300, the threshold needed to complete its going-private transaction. The board concluded that the reverse split had become too costly after certain investors distributed holdings across multiple small accounts to maximize fractional share payouts, significantly increasing the projected expense of that strategy. By shifting to the self-tender approach, Anebulo is seeking a more economically efficient path to delisting and deregistration while retaining the option to revisit a reverse split or other structural transaction in the future if conditions change.
The most recent analyst rating on (ANEB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.